Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of rabies vaccine for human and its use

A rabies vaccine and a new technology, applied in the field of human rabies vaccine and its preparation, can solve the problems of granulomatous inflammation, contact allergic reaction, local reaction, etc., and achieve the reduction of inflammatory reaction, reduction of inflammatory nodules, The effect of reducing side effects

Inactive Publication Date: 2006-08-30
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] ①Long use time: It has been used since 1926; ②Safe and effective; ③Inexpensive; ④Widely used; ⑤Weak adjuvant effect or no adjuvant activity for some vaccines; ⑥Easy to induce the expression of IgE; Erythema, subcutaneous nodules, contact allergic reactions, granulomatous inflammation, etc., and some even have serious local reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Embodiment 1, the preparation method of the nano aluminum adjuvant involved in the present invention

[0030] Take a certain amount of AlCl3, cyclohexane and distilled water in a beaker, then add the benzalkonium bromide-n-octanol-cyclohexane-AlCl3 solution system, and then stir with a high-speed dispersing homogenizer to make it emulsify into a micro lotion. Pour into a reaction bottle with a lid, heat and stir, slowly add excess ammonia water drop by drop, cover the lid, react for 3 hours, and use freeze-drying method or vacuum drying method to obtain Al(OH)3 sol.

[0031] The grain size of aluminum hydroxide aluminum hydroxide was determined by electron microscopy, and the particle size of aluminum hydroxide was 72 nanometers.

Embodiment 2

[0032] Embodiment 2, the preparation method of novel human rabies vaccine

[0033] The prepared nano-aluminum adjuvant is made into 0.1 mg per milliliter (with water as solvent), ultrasonically disperses the nano-aluminum adjuvant solution for 20 minutes, and the commercially available non-adjuvanted human rabies vaccine dose is 5.0 micrograms each, and human Rabies vaccine and nano-aluminum adjuvant were mixed at a volume of 3:1, adsorbed at 4°C for one week, centrifuged at 15,000 rpm for 30 minutes, and the concentration of Rabies v antigen in the supernatant was detected by ELISA double antibody sandwich method. According to the method described above, the amount of the new human rabies vaccine adsorbed on the nano-aluminum adjuvant per unit mass is 10-20 times higher than that of the conventional aluminum adjuvant.

Embodiment 3

[0034] Embodiment 3, the result of immunizing mice with novel human rabies vaccine of the present invention

[0035] Main reagents and their preparation

[0036] Coating diluent (0.05mol / L sodium carbonate-sodium bicarbonate buffer, pH9.6) composition:

[0037] Na2CO3 1.5g, NaHCO3 2.9g, Na2N3 0.2g, add double distilled water to 1000ml, adjust to pH9.6.

[0038] Blocking solution (5% calf serum / PBS solution) composition:

[0039] Calf serum 50ml, add PBS (pH7.4) 950ml.

[0040] Phosphate buffer saline (PB)

[0041] A liquid (0.2mol / L sodium dihydrogen phosphate aqueous solution) composition: NaH2PO4·H2O 27.6g dissolved in ultrapure water 1000ml.

[0042] B solution (0.2mol / L disodium hydrogen phosphate aqueous solution) composition: Na2HPO4·7H2O 53.6g (or Na2HPO4·12H2O 71.6g or Na2HPO4·2H2O 35.6g) dissolved in ultrapure water 1000ml.

[0043] Sample diluent (PBS, 0.01mol / L phosphate-buffered saline) components: PB A solution 19ml; PB B solution 81ml; NaCl 18.5g; ultrapure ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

A human rabies vaccine is prepared from the existing rabies vaccine without adjuvant through adsorbing it by the aluminum hydroxide nanoparticles. Its adsorbed capacity is increased by 10-20 time. It can be used for emergency inoculation for preventing rabies as it has the fast release effect.

Description

technical field [0001] The invention relates to a human rabies vaccine and a preparation method thereof, in particular to a rabies vaccine containing nano aluminum adjuvant and a preparation method thereof. technical background [0002] Rabies is an acute infectious disease caused by rabies virus that can only be prevented by vaccines and hyperimmune serum, with a case fatality rate of 100%, which is the acute infectious disease with the highest case fatality rate, and there is no clinically effective therapy [Jacob H, ShmuelR, Michael G , et al. Successful Postexposure Rabies Prophylaxis after Erroneous Starting Treatment. Preventive Medicine. 1999; 29: 28-31]. Once people have the possibility of being infected by rabies virus, they often adopt emergency vaccination. According to the characteristics of rabies, early antibody production and high titer are required [Hanion CA, Niezgoda M, Morrill PA, et al. The incurable woundrevisited: progress in human rabies prevention? ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/205A61P31/14
Inventor 吕凤林何萍
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com